Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review
La medicación diaria supervisada para el tratamiento con agonistas opiáceos (TAO) se ha identificado como un obstáculo para la retención del tratamiento. Las directrices canadienses sobre el TAO establecen los criterios de la dosis para llevar a casa (DTH); sin embargo, los prescriptores del TAO uti...
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| অন্যান্য লেখক: | |
| বিন্যাস: | গ্রন্থ |
| ভাষা: | স্প্যানিশ ইংরেজি |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | Path Enlace web |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
অনুরূপ উপাদানগুলি: Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review
- Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
- Characteristics of methadone-related overdose deaths and comparisons between those dying on and off opioid agonist treatment (OAT): A national cohort study
- MEDICAL MARIJUANA USE ISSUE TAKES MANY TURNS: HERE'S ONE
- SHOULD PEOPLE TAKING OPIOIDS FOR MEDICAL REASONS BE ALLOWED TO WORK AND DRIVE?
- Barriers to discontinuing benzodiazepine receptor agonists in older adults: a survey of older adults across Europe
- Canadian clinical guidelines on social isolation and loneliness in older adults